Breaking News

Bora Pharmaceuticals Makes Strategic Investment in Tanvex Biopharma

Will combine their biomanufacturing facilities to create a global service for biologics development and supply.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bora Pharmaceuticals Co., Ltd. has made a strategic investment in Tanvex Biopharma Co., Ltd., under which Bora Biologics, a subsidiary of Bora and specialist large molecule CDMO, and Tanvex will combine their biomanufacturing facilities to create a global service for biologics development and supply. The investment combines Bora’s CDMO capabilities with Tanvex’s scale, development expertise and U.S. FDA-approved commercial-scale facility in San Diego, CA. Additionally, Bobby Sheng, Chairman and ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters